February 18, 2019

15 Feb 2019 | UK | Roche | In its final appraisal of pertuzumab, the National Institute for Health and Care Excellence (NICE) has recommended it for the treatment of lympth node-positive disease. The final appraisal comes following the promise of a large discount offer...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags